Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.

University of Connecticut School of Business, USA.
The Journal of Law Medicine &amp Ethics (Impact Factor: 0.94). 02/2009; 37(2):209-21. DOI: 10.1111/j.1748-720X.2009.00366.x
Source: PubMed

ABSTRACT This manuscript addresses how developing countries can maximize access to essential medicines and minimize unwanted side-effects within the legal environment of a compulsory license regime. While compulsory licensing can play a role in improving public health, external social and political conditions must be considered in order to make licensing an effective practice.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this Comment, the author traces the relevant legislative history pertaining to compulsory licensing of patented pharmaceuticals from the TRIPS Agreement of 1994 to the 2003 waiver to, and later proposed amendment of, article 31, which enables poor countries to obtain needed medicines from other countries that possess manufacturing capacity. The Comment then evaluates recent, controversial uses of the relevant legislative machinery as viewed from different critical perspectives. The Comment shows how developing countries seeking access to essential medicines can collaborate in ways that would avoid undermining incentives to innovation and other social costs attributed to compulsory licensing. It ends by defending the legality of recent measures taken to promote public health in developing countries, and by reminding developed countries that unilateral retaliation against such measures is demonstratably illegal under WTO foundational law and jurisprudence.
    The Journal of Law Medicine &amp Ethics 05/2009; 37(2):247 - 263. · 0.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Major breakthroughs have been realized in controlling cancer in the past five decades. However, for patients in low- and middle-income countries (LMICs), many of these advances are nothing but an aspiration and hope for the future. Indeed, the greatest challenge we face in oncology today is how to reconcile small, incremental and significant improvements in the management of cancer with the exponentially increasing costs of new treatments. Emerging economies are attempting to address this important issue of access to cancer medications. In this Review, we examine how LMICs are using generic and biosimilar drugs, expanding participation in clinical trials, implementing universal health-care schemes to pool resources, and using compulsory licensing schemes as well as increasing multiple-stakeholder public-private partnerships to increase access to cancer medications for their citizens. Any truly effective programme will require multiple stakeholder involvement-including governments, industry and civil society-to address the issue of access to medication. Only with the creation of a global entity to fight cancer that is supported by a global fund-for example, in the mould of the GAVI alliance and the International Finance Facility for Immunization-will we truly be able to improve cancer care in LMICs and drive down the high mortality rates in these regions.
    Nature Reviews Clinical Oncology 04/2013; · 15.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Management of pandemic influenza relies on complex coordination of many different dimensions of the health and social care systems, emergency services, levels of national and local government, civil society, communications and media, and cultural expectations. Law is one small but important component of those arrangements, which touch on fundamental ethical debates. This review demonstrates that the Asian region is actively engaging those issues in diverse ways in light of their varied socioeconomic and cultural backgrounds, but scope remains for prioritising further research into these relationships.
    Asia-Pacific Journal of Public Health 05/2011; 23(3):419-30. · 1.11 Impact Factor